2789-25-5

Basic information

• Product Name: 4-Amino-2-chloro-3-nitropyridine
• Synonyms: 2-CHLORO-3-NITROPYRIDIN-4-AMINE;4-AMINO-2-CHLORO-3-NITROPYRIDINE;4-Amino-3-nitro-2-chloropyridine;2-Chloro-3-nitro-4-aminopyridine;2-Chloro-3-nitropyridin-4-amine ,98%;2-Chloro-3-nitro-4-pyridinamine;2-chloro-3-nitro-;2-Chloro-4-aMino-3-nitropyridine
• CAS NO: 2789-25-5
• Molecular Formula: C₅H₄ClN₃O₂
• Molecular Weight: 173.56
• Product Categories: Pyridine;Pyridines;Heterocycle-Pyridine series;amine|alkyl chloride |nitro-compound
• Mol File: 2789-25-5.mol
• Article Data: 16

Chemical Properties

• Melting Point: 205-207 °C (decomp)
• Boiling Point: 392.8 °C at 760 mmHg
• Flash Point: 191.4 °C
• Appearance: /
• Density: 1.596 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.63±0.42(Predicted)
• CAS DataBase Reference: 4-Amino-2-chloro-3-nitropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-2-chloro-3-nitropyridine(2789-25-5)
• EPA Substance Registry System: 4-Amino-2-chloro-3-nitropyridine(2789-25-5)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-43-36/37/38
• Safety Statements: 36/37-37/39-26
• Hazardous Substances Data: 2789-25-5(Hazardous Substances Data)

Usage

Chemical Properties

Yellow solid

Uses

4-Amino-2-chloro-3-nitropyridine is used as a reagent in the synthesis of imidazopyridine-based fatty acid synthase inhibitors which show anti-HCV activity. Also used as a reagent in the synthesis of acyclic nucleotides that are related to clitocine, which exhibit antiviral activity.

Upstream product

• 14432-16-7 2-chloro-4-nitropyridine-N-oxide 
• 2402-95-1 2-chloropyridine-N-oxide 
• 109-09-1 2-chloropyridine 
• 89282-12-2 2,4-dihydroxy-3-nitropyridine 
• 14432-12-3 4-Amino-2-chloropyridine 
• 5975-12-2 2,4-dichloro-3-nitro-pyridine 
• 14432-13-4 (2-chloro-pyridin-4-yl)-nitro-amine 
• 7664-93-9 sulfuric acid 
• 5470-18-8 2-Chloro-3-nitropyridine 

Downstream Products

• 39217-08-8 2-chloropyridine-3,4-diamine 
• 24501-21-1 2,4-diamino-3-nitropyridine 
• 87871-08-7 erythro-9-(2-hydroxy-3-nonyl)-1-deazaadenine 
• 121370-68-1 tert-butyl 4-(1H-imidazo[4,5-c]pyridin-4-yl)piperazine-1-carboxylate 
• 6811-77-4 4-amino-1H-imidazo[4,5-b]pyrimidine 

Relevant articles and documents

Imidazopyridine-Based 5-HT6Receptor Neutral Antagonists: Impact of N1-Benzyl and N1-Phenylsulfonyl Fragments on Different Receptor Conformational States

G-protein coupled receptors (GPCRs) exist in an equilibrium of multiple conformational states, including different active states, which depend on the nature of the bound ligand. In consequence, different conformational states can initiate specific signal transduction pathways. The study identified compound 7e, which acts as a potent 5-hydroxytryptamine type 6 receptor (5-HT6R) neutral antagonist at Gs and does not impact neurite growth (process controlled by Cdk5). MD simulations highlighted receptor conformational changes for 7e and inverse agonist PZ-1444. In cell-based assays, neutral antagonists of the 5-HT6R (7e and CPPQ), but not inverse agonists (SB-258585, intepirdine, PZ-1444), displayed glioprotective properties against 6-hydroxydopamine-induced and doxorubicin-induced cytotoxicity. These suggest that targeting the activated conformational state of the 5-HT6R with neutral antagonists implicates the protecting properties of astrocytes. Additionally, 7e prevented scopolamine-induced learning deficits in the novel object recognition test in rats. We propose 7e as a probe for further understanding of the functional outcomes of different states of the 5-HT6R.

Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy

Novel substituted purine isosters, were designed and synthesized as potential inhibitors of the Epidermal Growth Factor Receptor (EGFR). The compounds were rationally designed through bioisosteric replacement of the central quinazoline core of lapatinib, an approved drug that inhibits both EGFR and HER2, another important member of this family of receptors. The new target molecules were evaluated as inhibitors of receptor phosphorylation at the cellular level, for their direct inhibitory action on the intracellular receptor kinase domain and for their cytotoxicity against the non-small cell lung cancer cell line A549 and breast cancer HCC1954, cell lines which are associated with overexpression of EGFR and HER2, respectively. The most potent derivatives were further studied for their cellular uptake levels and in vivo pharmacokinetic properties. One compound (23)displayed a noteworthy pharmacokinetic profile, and higher intracellular accumulation in comparison to lapatinib in the A549 cells, possibly due to its higher lipophilicity. This lead compound (23)was assessed for its efficacy in an EGFR positive xenograft model, where it successfully inhibited tumor growth, with a similar efficacy with that of lapatinib and with minimal phenotypic toxicity.

Pharmaceutical composition for treating hyperplasia of mammary glands as well as preparation method and application of pharmaceutical composition

The invention belongs to the technical field of medicine and particularly relates to a pharmaceutical composition for treating hyperplasia of mammary glands. The pharmaceutical composition has the structure in a formula shown in the description. The invention also relates to a preparation method and an application of the pharmaceutical composition for treating hyperplasia of mammary glands. The medicine can relieve mammary tissue hyperplasia lesion, has significant treatment effects on patients suffering from hyperplasia of mammary glands and is stable in curative effect, high in cure rate andlow in recurrence rate.